Curis (NASDAQ:CRIS) Stock Price Passes Above Two Hundred Day Moving Average of $10.73

Curis, Inc. (NASDAQ:CRIS) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $10.73 and traded as high as $15.27. Curis shares last traded at $15.27, with a volume of 22,370 shares trading hands.

Analyst Ratings Changes

Separately, HC Wainwright lowered their target price on Curis from $51.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, February 9th.

Curis Price Performance

The firm has a market capitalization of $89.65 million, a PE ratio of -1.63 and a beta of 3.72. The company has a 50-day moving average price of $11.51 and a 200 day moving average price of $9.95.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Thursday, February 8th. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.91) by ($0.12). The company had revenue of $2.70 million for the quarter, compared to the consensus estimate of $2.95 million. Curis had a negative net margin of 473.04% and a negative return on equity of 169.22%. During the same quarter in the previous year, the business earned ($2.40) EPS. As a group, research analysts anticipate that Curis, Inc. will post -5.92 earnings per share for the current year.

Hedge Funds Weigh In On Curis

Several hedge funds have recently added to or reduced their stakes in CRIS. HRT Financial LP bought a new position in shares of Curis during the fourth quarter valued at approximately $29,000. Engineers Gate Manager LP bought a new position in Curis in the 1st quarter valued at $32,000. UBS Group AG increased its stake in Curis by 183.6% in the third quarter. UBS Group AG now owns 51,332 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 33,231 shares during the period. Virtu Financial LLC bought a new stake in shares of Curis during the fourth quarter worth $51,000. Finally, Bank of Montreal Can bought a new stake in shares of Curis during the second quarter worth $59,000. 29.97% of the stock is currently owned by institutional investors.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.